Tempus has announced its acquisition of Personalis, aiming to enhance its capabilities in minimal residual disease (MRD) technology, a key area in oncology.
This strategic move is seen as a significant opportunity for Tempus, potentially valued at $20 billion, as it seeks to broaden its influence across the cancer care spectrum. The integration of Personalis' advanced MRD technology into Tempus' existing multimodal data and AI platform is expected to enhance cancer monitoring and improve clinical decision-making.
Tempus CEO Eric Lefkofsky highlighted that this acquisition builds on a prior partnership initiated in November 2023, which involved an investment in Personalis and the commercialization of its NeXT Personal MRD test. He emphasized the transformative potential of MRD technology in monitoring cancer patients, particularly as the market for MRD continues to grow.
With projections indicating that new cancer diagnoses in the U.S. could surpass 2 million by 2026, the demand for effective long-term monitoring solutions is becoming increasingly urgent. The ultra-sensitive nature of Personalis' MRD tests positions Tempus to meet this critical need as they prepare for the acquisition's anticipated closure in late 2026 or early 2027.